-transparent.png){kind=logo}
Labetalol optimal doses for Indonesian patients were investigated in an open, multicentre, unforced titration dose-finding study involving 134 essential hypertensive outpatients with baseline supine DBP (SuDBP) of 105-129 mmHg. Labetalol was started at 50 mg bid and as necessary increased by 50 mg bid every 2 weeks. Evaluable for efficacy were 105 moderate and 25 moderately severe hypertensives. Labetalol was effective (decreased SuDBP to 90 mmHg or less) in 75% of patients and moderately effective (decreased SuDBP at least 10% of baseline but did not reach 90 mmHg) in 10%. The cumulative percent responders were 15, 49, 79 and 85% to final daily doses of 100, 200, 300 and 400 mg, respectively. Adverse reactions were found in 31% of patients, the most frequent were gastrointestinal complaints causing 3 withdrawals. It is concluded that labetalol optimal doses for Indonesian moderate to moderately severe hypertensives range from 100 to 300 mg daily in 2 divided doses.
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
September 1985,
Journal of clinical pharmacology,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
April 1980,
The Medical journal of Australia,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
January 1981,
Acta medica Scandinavica. Supplementum,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
January 1986,
Journal of clinical pharmacology,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
April 1956,
The Journal of the American Osteopathic Association,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
June 1998,
Vnitrni lekarstvi,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
February 2007,
The British journal of dermatology,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
January 2010,
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
June 1982,
British journal of clinical pharmacology,
I Darmansjah, and
A Setiawati, and
P Prabowo, and
E Sukandar, and
I Parsoedi, and
Ardaya, and
B Bahry, and
J Jusman, and
E Anggraeni
February 1991,
Journal of clinical pharmacology,
